KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Other Non-Current Liabilities: 2009-2025

Historic Other Non-Current Liabilities for Novavax (NVAX) over the last 12 years, with Sep 2025 value amounting to $263.5 million.

  • Novavax's Other Non-Current Liabilities fell 17.38% to $263.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.5 million, marking a year-over-year decrease of 17.38%. This contributed to the annual value of $359.6 million for FY2024, which is 985.46% up from last year.
  • Latest data reveals that Novavax reported Other Non-Current Liabilities of $263.5 million as of Q3 2025, which was down 8.38% from $287.6 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Other Non-Current Liabilities ranged from a high of $359.6 million in Q4 2024 and a low of $20.6 million during Q2 2021.
  • Its 3-year average for Other Non-Current Liabilities is $217.0 million, with a median of $287.6 million in 2025.
  • In the last 5 years, Novavax's Other Non-Current Liabilities plummeted by 62.16% in 2023 and then surged by 985.46% in 2024.
  • Quarterly analysis of 5 years shows Novavax's Other Non-Current Liabilities stood at $42.1 million in 2021, then spiked by 32.23% to $55.7 million in 2022, then slumped by 40.52% to $33.1 million in 2023, then spiked by 985.46% to $359.6 million in 2024, then declined by 17.38% to $263.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $263.5 million for Q3 2025, versus $287.6 million for Q2 2025 and $313.7 million for Q1 2025.